SCHEMBL970746

SCHEMBL970746

CCS(=O)(=O)O.O=S(=O)(O)CCO

nearest known ligand 0.43

Known targets — ChEMBL curated mechanism

FGFR1FGFR2FGFR3FGFR4FLT1FLT4KDRPDGFRAPDGFRB

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
BLM P54132 2/20 0.43
PTGS1 P23219 1/20 0.43
PDE4A P27815 1/20 0.43
SLC6A6 P31641 1/20 0.43
CYP2C19 P33261 1/20 0.43
APP P05067 1/20 0.39
POLB P06746 3/20 0.34
ALDH1A1 P00352 2/20 0.34
RAB9A P51151 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MAPT P10636 2/20 0.34
KDM4E B2RXH2 2/20 0.34
NPC1 O15118 1/20 0.34
ALOX15 P16050 1/20 0.34
BRCA1 P38398 1/20 0.34
HTT P42858 1/20 0.34
GMNN O75496 1/20 0.34
PKM P14618 1/20 0.34
THPO P40225 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propane SCHEMBL28339028 0.94 LMNA (0.43) LMNABLMPTGS1PDE4ASLC6A6
Alcohol SCHEMBL490837 0.94 LMNA (0.43) LMNABLMPTGS1PDE4ASLC6A6
Methyl Alcohol SCHEMBL28253720 0.90
SCHEMBL827 0.90
SCHEMBL249947 0.90 LMNA (0.50) LMNABLMPTGS1PDE4ASLC6A6
SCHEMBL28031140 0.88 LMNA (0.39) LMNABLMPTGS1PDE4ASLC6A6
SCHEMBL18155126 0.88 LMNA (0.43) LMNABLMPTGS1PDE4ASLC6A6
SCHEMBL19814012 0.88
SCHEMBL1304651 0.87
SCHEMBL1138506 0.87

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119789853-A Dexmedetomidine for the treatment of sleep disorders 苏黎世大学 2025-04-08 CN disclosed
US-9133204-B2 5-membered heterocyclic amides and related compounds H. LUNDBECK A/S (DK) 2015-09-15 US disclosed
EP-2178865-B1 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS LUNDBECK H AS (DK) 2015-08-19 EP disclosed
EP-2245029-B1 HETEROCYCLIC INHIBITORS OF STEAROYL-COA DESATURASE NOVARTIS AG (CH) 2015-04-15 EP disclosed
US-20150005293-A1 5-Membered Heterocyclic Amides And Related Compounds MINDIMMUNE THERAPEUTICS, INC. 2015-01-01 US disclosed
US-20140038955-A1 HETEROARYL AMIDE ANALOGUES AS P2X7 ANTAGONISTS H. LUNDBECK A/S (DK) 2014-02-06 US disclosed
EP-2096923-B1 HETEROARYL AMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2014-01-22 EP disclosed
US-8580812-B2 Heteroaryl amide analogues as P2X7 antagonists H. LUNDBECK A/S (DK) 2013-11-12 US disclosed
US-20130172549-A1 Heteroaryl amide derivatives H. LUNDBECK A/S (DK) 2013-07-04 US disclosed
US-8466296-B2 Compounds and processes for preparing substituted aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-ones LIGAND PHARMACEUTICALS (US) 2013-06-18 US disclosed
WO-2008060568-A2 AMIDE-SUBSTITUTED ARYL PIPERIDINES NEUROGEN CORPORATION (US) 2008-05-22 WO disclosed
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION 2008-02-28 US disclosed
WO-2008002849-A2 ARYL SULFONES NEUROGEN CORPORATION (US) 2008-01-03 WO disclosed
WO-2007146122-A2 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-12-21 WO disclosed
WO-2007140383-A2 SPIROCYCLIC SULFONAMIDES AND RELATED COMPOUNDS NEUROGEN CORPORATION (US) 2007-12-06 WO disclosed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 WO disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
WO-2007106349-A2 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-09-20 WO disclosed
US-5504094-A Use of bengothiophenls to treat pain due to an excess of neuropeptide y ELI LILLY AND COMPANY (US) 1996-04-02 US disclosed
US-4318926-A Method of curing or alleviating herpes infections and pharmaceutical compositions suitable therefor CIBA-GEIGY CORPORATION (US) 1982-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES HRH3, HRH4, HRH2 LMNA 4534/4885BLM 4596/4885PTGS1 1403/4885
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues HRH3, HRH4, HRH1 LMNA 4138/4885BLM 4367/4885PTGS1 1912/4885
US-20150005293-A1 5-Membered Heterocyclic Amides And Related Compounds GPR35, HCAR2, HCAR1 LMNA 3768/4885BLM 4816/4885PTGS1 851/4885
US-20130172549-A1 Heteroaryl amide derivatives HCAR2, PIGS, GPR52 LMNA 4016/4885BLM 4714/4885PTGS1 2515/4885
US-20140038955-A1 HETEROARYL AMIDE ANALOGUES AS P2X7 ANTAGONISTS P2RX7, P2RX3, P2RX2 LMNA 1890/4885BLM 3056/4885PTGS1 1983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.